Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics Inc. (DGX) had 5,563,421 common shares reported as beneficially owned by State Street Corporation, representing 5% of the class. State Street reported shared voting power over 3,406,108 shares and shared dispositive power over 5,557,626 shares; sole voting and dispositive power were each 0 shares.
Quest Diagnostics Inc. (DGX) officer Patrick Plewman, identified in the remarks as the same person as Thomas P. Plewman, reported an intended sale of 11,717 common shares, with an aggregate market value of $3,015,252.78 and an approximate sale date of November 9, 2026. A Rule 10b5-1 plan adoption or instruction date of August 11, 2026, is listed.
The shares listed include 650 acquired through restricted stock vesting on February 24, 2025, and 11,067 acquired through a stock option exercise for cash on November 9, 2026.
Quest Diagnostics Inc. reported that SVP, Regional Businesses Subu Ramachandran received an award of 1,386 stock options to acquire common stock at an exercise price of $248.61 per share on November 3, 2026. The award also included 352 restricted share units; direct common-stock holdings following that award were 2,832 shares. The options vest in three equal annual installments beginning on the first anniversary of the grant date and expire on November 3, 2036.
Quest Diagnostics Inc. Executive Vice President Catherine T. Doherty exercised options for 22,105 shares at $121.8050 per share on November 3, 2026; the reported option balance afterward was 0. She received 4,827 restricted stock units and sold 22,105 shares that day under a Rule 10b5-1 sales plan she adopted. The seven weighted-average sale prices were 3,818 at $245.4519, 5,990 at $246.2649, 1,151 at $246.9835, 2,358 at $248.3838, 3,004 at $249.4035, 2,877 at $250.4882, and 2,907 at $251.2386 per share. A separate indirect holding entry reports 4,552 shares through the Company's 401(k) and/or Supplemental Deferred Compensation Plan; the count is based on the company stock-fund account balance, which includes some money market instruments.
Quest Diagnostics (DGX) reported that Mark E. Delaney, SVP & Chief Commercial Officer, acquired 2,615 shares of common stock on November 3, 2026, through an award of restricted stock units. His reported direct holdings following the award were 12,975 shares.
Quest Diagnostics Inc. reported that Subu Ramachandran, SVP, Regional Businesses, directly held 2,480 common shares as of November 1, 2026. He also reported seven direct non-qualified stock option holdings tied to common stock. One listed position covers 1,968 underlying common shares at an exercise price of $204.9600 per share and expires February 18, 2036.
Quest Diagnostics Inc. (DGX) officer Catherine T. Doherty reported a proposed sale of 22,105 common shares with an aggregate market value of $5,584,607.20. The approximate sale date is November 3, 2026. The shares are listed as acquired from the issuer through a stock option exercise on that date.
Quest Diagnostics Inc. (DGX) director Gary M. Pfeiffer sold 1,203 shares of common stock at $243 per share on October 26, 2026. The sale was effected pursuant to a Rule 10b5-1 sales plan adopted by Gary M. Pfeiffer. He directly held 29,802 shares after the transaction.
Quest Diagnostics Inc. Director Gary M. Pfeiffer reported a proposed sale of 1,203 common shares, with an aggregate market value of $292,329, for approximately October 26, 2026. The notice identifies Fidelity Brokerage Services LLC as the broker and the NYSE as the market. The shares were acquired from the issuer through restricted stock vesting on May 15, 2026, as compensation.
Quest Diagnostics Inc. (DGX) director Robert B. Carter acquired 10 shares of common stock at $235.93 per share on October 21, 2026, through a dividend reinvestment plan administered by his broker. His directly held position was 3,874 shares after the transaction. The shares were eligible for deferred reporting under Rule 16a-6, and Carter chose to report the acquisition early.